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In terms of nuclear decay 18F-fluorine is the most ideal PET nuclide but its short t1/2 precludes its use for directly labelling whole antibodies due to their long blood residence times. Pre-targeted imaging using affinity systems such as NeutravidinTM -biotin facilitate the application of short-lived nuclides by their attachment to biotin for imaging cell surface proteins targeted with NeutravidinTM -conjugated antibodies. 

Methods
Boroaryl functionalised biotin was prepared with a PEG linker and radiolabelled by incubation with18F-fluorine in acidified aqueous solution. Cells expressing high (SKBr3), medium (MDA-MB-453) and low (MDA-MB-468) levels of HER-2 were pre-incubated with NeutravidinTM -conjugated Trastuzumab, washed,  then incubated with 18F-PEG-biotin. 

Results
The 18F-fluorination of boroaryl-PEG-biotin was much more efficient than reported for other versions of boroaryl-biotin. The novel 18F-PEG-biotin was demonstrated to bind to HER2-expressing cells in-vitro pre-incubated with NeutravidinTM –conjugated trastuzumab.

Conclusion
Biotin can be functionalised with boroaryl and readily 18F-radiolabelled in aqueous solution and will bind to cells pre-incubated with NeutravidinTM -antibody conjugates.

Keywords






















In terms of its nuclear properties 18F is the most ideal PET isotope for imaging due to its simple decay and emission properties with high (97%) positron abundance and relatively low positron emission energy (0.635MeV max). In addition, all PET facilities with cyclotrons produce 18F, which is consequently the most readily available PET isotope. 

Currently 2-[18F]fluoro-2-deoxy-d-glucose (FDG), a glucose analogue, is by far the most widely available PET tracer being utilized in about 90% of all PET investigations (Coenen et al 2010). However FDG is a non-specific tracer taken up by all glucose-utilizing tissue.  In contrast macromolecules such as antibodies selectively accumulate in tissue expressing specific cell surface molecules. These include the therapeutic antibodies cetuximab and trastuzumab which target HER-1 and HER-2 expressing tumour tissue respectively (Rusnak et al 2007).

Monoclonal antibodies and derivatives such as diabodies (Wu et al 1996) have a high avidity for their target molecules but are too large to be rapidly cleared from the bloodstream so unsuitable for direct labelling with 18F which has a half-life of only 110min. A strategy for utilizing 18F for in-vivo diagnosis which enables the use of high molecular weight antibodies is to pre-target the antigen of interest with the antibody, conjugated to NeutravidinTM (a neutral and deglycosylated version of avidin which exhibits lower levels of non-specific cell binding than does avidin) which has a high affinity for biotin. Several days later after the unbound antibody conjugate has cleared from the blood (this may be assisted by addition of a clearing molecule), radiolabeled biotin, which being small and water soluble is rapidly cleared from the blood, is administered and the patient scanned after 1 or 2 hours. This has been carried out with nuclides including 68Ga (Griffiths et al 2004) but is applicable to 18F. It is also well established that using pre-targeted imaging improves image quality when compared with the administration of directly labelled antibodies (Goldenburg et al 2006).

In this paper we describe the synthesis of a model biotin conjugate that is functionalized with difluoroboroaryl to facilitate 18F-radiolabelling using an aqueous 18F-fluorination procedure. The in-vitro binding of this tracer (18F-PEG-biotin) is then demonstrated using HER-2 expressing cells pre-incubated with NeutravidinTM-conjugated trastuzumab. 










Melting points were recorded on a Gallenkamp melting point apparatus and are uncorrected. 1H and 13C nuclear magnetic resonance spectra were recorded on a Bruker AC 250 or a Varian 400 MHz Unity INOVA spectrometer. 11B and 19F nuclear magnetic resonance spectra were recorded on a Varian 600/54 PS spectrometer in the Department of Chemistry at Aberdeen University. Mass spectra were obtained on a Waters LCT Premier XE mass spectrometer using electrospray ionization at the University of Sheffield. NMR analyses in each of the methods section describing a synthesis are preceded by e.g. for proton data: δH (solvent, operating frequency). Mass spectroscopy are preceded by m/z (ESI).  

Synthesis of (2-{2-[2-(2-{2-[2-(2-{2-[5-(2-Oxo-hexahydro-thieno[3,4-d]imidazol-4-yl)-pentanoylamino]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethyl)-carbamic acid tert-butyl ester (1)

Addition of PEG linker to biotin:  A solution of biotin N-hydroxysuccinimide ester (25 mg, 73.2 μmol), O-(2-aminoethyl)-O'-[2-(Boc-amino)ethyl]-hexaethylene glycol (34 mg, 72.6 μmol) and triethylamine (8.0 mg, 11 μL, 78.9 μmol) was stirred in CHCl3 (2 mL) at room temperature under Ar for 15 hours. The reaction mixture was washed three times with H2O then dried (MgSO4​), filtered and evaporated to leave the product as a white solid. Analysis of product 1: 50 mg (100 %); δH(250 MHz; CDCl3) 1.40-1.77 (15 H, m), 2.18 (2 H, t, J 7.3), 2.70 (1 H, d, J 12.8), 2.85 (1 H, dd, J 12.5, 4.6), 3.06-3.12 (1 H, m), 3.25-3.60 (32 H, m), 4.23-4.28 (1 H, m), 4.43-4.48 (1 H, m), 5.09 (1 H, bs), 5.93 (1 H, bs), 6.80 (1 H, bs), 6.93 (1 H, bt); δC(62.5 MHz; CDCl3) 25.5, 28.0, 28.2, 28.3, 35.8, 39.0, 40.2, 40.4, 55.6, 60.1, 61.6, 69.8, 69.9, 70.1, 70.2, 70.3, 70.4, 79.0, 155.9, 164.2, 173.3; m/z (ESI) 695.3892 ([M+H]+. C31H59N4O11S requires 695.3901).

Synthesis of 5-(2-Oxo-hexahydro-thieno[3,4-d]imidazol-4-yl)-pentanoic acid [2-(2-{2-[2-(2-{2-[2-(2-amino-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethyl]-amide dihydrochloride (2)

Cleavage of the Boc protecting group: A 4 M solution of HCl in dioxane (1.6 mL, 6.40 mmol) was added to a solution of 1 (88 mg, 0.127 mmol) in MeOH (1.6 mL) and the mixture was stirred for 90 minutes at room temperature under Ar. The mixture was concentrated in vacuo to leave the product as a colourless oil. Analysis of product 2: 84 mg (99 %); δH(250 MHz; CD3OD) 1.37-1.42 (2 H, q, J 6.1), 1.52-1.67 (4 H, m), 2.26 (2 H, t, J 6.7), 2.76 (1 H, d, J 13.1), 2.97 (1 H, dd, J 12.5, 3.1), 3.18-3.23 (1 H, m), 3.32-3.37 (4 H, m), 3.60-3.69 (28 H, m), 4.38-4.43 (1 H, m), 4.57-4.62 (1 H, m).

Synthesis of 2,6-Difluoro-4-[(carboxy-methoxyimino)-methyl]-phenylboronic acid pinacol ester (3)

Oxime formation between the boroaryl group and an amino acid: A mixture of (O-carboxymethyl)hydroxylamine hemihydrochloride (171 mg, 1.57 mmol), 2,6-difluoro-4-formylphenylboronic acid pinacol ester (350 mg, 1.31 mmol) and Hünig’s base (102 mg, 137 µL, 0.787 mmol) was stirred in anhydrous acetonitrile (10 mL) containing 3 Å molecular sieves at room temperature under Ar for 2 hours. The solvent was evaporated and the residue dissolved in EtOAc. The ethyl acetate was washed once with H2O then dried (MgSO4), filtered and evaporated to leave a white solid. This was recrystallised from a mixture of petroleum ether 40/60 and EtOAc (4:1) to leave the product as a white solid. Analysis of product 3: 228 mg (51 %); m.p. 151-152° C; δH(250 MHz; CDCl3) 1.37 (12 H, s), 4.77 (2 H, s), 7.06 (2 H, d, J 7.6), 8.09 (1 H, s), 10.40 (1 H, bs); δC(62.5 MHz; CDCl3) 24.7, 70.5, 84.4, 109.8 (d, J 28), 136.5 (t, J 10), 148.5, 166.6 (dd, J 251, 13), 175.4; δB(192 MHz; CDCl3) 29.1; m/z (ESI) 342.1323 ([M+H]+. C15H19BF2NO5 requires 342.1324).

Synthesis of 2,6-Difluoro-4-{[2-oxo-2-(pentafluorophenoxy)-ethoxyimino]-methyl}-phenylboronic acid pinacol ester (4)

Activation of the carboxylic acid functional group: EDC hydrochloride (26 mg, 0.136 mmol) and pentafluorophenol (22 mg, 0.120 mmol) were added to a solution of 3 (40 mg, 0.117 mmol) in CHCl3 (1.5 mL) and the mixture was stirred at room temperature under Ar for 15 hours. The choloroform was evaporated and the residue dissolved in a mixture of EtOAc and H2O. The layers were separated and the organic portion dried (MgSO4), filtered and evaporated to leave the product as a colourless oil. Analysis of product 4: 59 mg (100 %); δH(250 MHz; CDCl3) 1.38 (12 H, s), 5.06 (2 H, s), 7.08 (2 H, d, J 6.7), 8.12 (1 H, s); δC(62.5 MHz; CDCl3) 24.7, 70.2, 84.5, 109.8 (d, J 28), 136.2 (t, J 11), 149.0, 165.6, 166.6 (dd, J 251, 14); δB(192 MHz; CDCl3) 29.4.

Synthesis of 2,6-Difluoro-4-{[2-oxo-2-(2-{2-[2-(2-{2-[2-(2-{2-[5-(2-oxo-hexahydro-1H-thieno[3,4-d]imidazol-4-yl)-pentanamido]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethylamino)-ethoxyimino]-methyl}-phenylboronic acid pinacol ester (5)













SKBr3, MDA-MB-453 and MDA-MB-468 cells (obtained from the American Tissue Culture Collection (ATCC)) were maintained in 75cm2 tissue culture flasks in Dulbecco’s Modified Eagles Medium (Gibco UK) containing 10% Foetal Bovine Serum (Gibco UK). Confluent flasks were trypsinzed with 5ml of trypsin and neutralised with complete medium then used to set up the 25cm2 flasks. Several days later when the cells in each flask were about 80% confluent they were used for the determination of targeted 18F-PEG-biotin binding. 

NeutravidinTM conjugation to trastuzumab

Trastuzumab was purified from10mg of Herceptin (Roche) dissolved in 2ml of distilled water by filtration though an Amicon Ultra centrifugal filter device (Millipore USA) with a molecular weight cut off 30KDa by centrifuging at 1500g for 20min at room T to remove salts and buffers that are present in the clinical preparation and may interfere with the conjugation procedure. PBS (2ml) was then added to the retained trastuzumab and the filter centrifuged at 5000g for a further 20mins. The washed trastuzumab retained by the filter was then resuspended in 0.2ml PBS.   The concentration of trastuzumab was then determined by measurement of absorbance at 280nm using a Helios UV spectrophotometer (Thermo Spectronic UK) using the Extinction coefficient for antibodies of 210,000 M-1cm-1. 

Reduction of thiol groups in trastuzumab:  To 1mg of trastuzumab was added 1mg of mercaptoethanol (ME) in PBS pH 7.2 and the solution incubated at 37oC for 90 min. ME was then removed from the reduced trastuzumab by filtration though an Amicon Ultra centrifugal filter device (Millipore USA) with a molecular weight cut off 30KDa by centrifuging at 1500g for 20min followed by 2 washes with 1ml of PBS. The reduced trastuzumab was then incubated immediately with the commercially available product, maleimide-activated NeutravidinTM (1mg) (Thermo Scientific UK),  in maleimide conjugation buffer (sodium phosphate (0.1M), EDTA (5mM) pH 7.5) and left overnight at room T. The thiol reduction procedure and conjugation with maleimide-activated  NeutravidinTM is described in the instruction sheet that accompanies the maleimide-activated  NeutravidinTM kit (Thermo Scientific UK) which was adhered to.

Pre-incubation with NeutravidinTM conjugated trastuzumab and incubation with 18F-biotin

NeutravidinTM conjugated trastuzumab (containing 1mg of trastuzumab) supplemented with 1.5mg of biotin-saturated NeutravidinTM (6 fold excess of NeutravidinTM in NeutravidinTM conjugated trastuzumab) to reduce non-HER2 binding) was added to 5ml of medium and incubated with flasks (0.3ml per flask) of MDA-MB-453, MDA-MB468 or SKBr3 cells in triplicate. To each flask was added 0.3ml of medium containing 37KBq of 18F-PEG-biotin. Incubation was continued for 1h after which the flasks were flushed 3X with 5ml of PBS to remove unbound 18F-PEG-biotin. Cells were removed by trypsinisation with 0.3ml of trypsin and cell associated 18F determined using a well counter (the cells were not separated from the trypsin/media so any 18F removed by the trypsin would still be measured). The cells were then dissolved overnight in 0.1ml of NaOH (1M) then neutralised with 0.1ml of HCl (1M) and protein content determined using the bicinchoninic acid protein assay kit (Sigma-Aldrich UK). The protein data was then used to normalise the radioactive binding allowing comparison of data between each cell type.

Preparation of biotin-saturated NeutravidinTM.





Labelling of BA-PEG-biotin with 18F

Figure 1 shows the time course of labelling with 18F of 0.1 µmoles and 0.5 µmoles of BA-PEG-biotin with 18F. The initial rate of labelling is more rapid with 0.5 µmoles but at both concentrations the maximum labelling efficiency plateaus at about 65%. The specific activity achieved using 0.1 µmol of precursor is 100MBq/µmol using about 20MBq of 18F-fluroride and could be increased by using higher activity of 18F-fluoride (potentially GBqs).  Figure 2 shows a UV (210nm) absorbance and radio-chromatogram from 30min incubation of BA-PEG-biotin with 18F-fluoride.  A similar sample was also applied to a TLC silica plate and run using a mobile phase of ethanol:water (95%:5%) until it reached 70mm. The result shown in figure 3 shows 18F-fluoride at the origin and the product 18F-PEG-biotin at 35 mm with an Rf of 0.5. Purified and neutralised 18F-PEG-biotin preparations were maintained in media for 0.5h and 2h then applied to a silica TLC plate using ethanol:water (95%:5%) as the mobile phase. Less than 1% and 5% of the 18F were in the form of free fluoride after 0.5 and 2h respectively. 

Binding of 18F-PEG-biotin to cells pre-incubated with NeutravidinTM conjugated trastuzumab 





Biotin has been labelled with 99mTc (Kleine et al 2008), 111In (Lazzeri et al 2004) and 64Cu (Lewis et al 2003) positron emitting isotopes for SPECT and PET imaging and with cytotoxic beta-emitting nuclides for therapy (Breitz et al 2000). Simpson et al (2011) recently reported the labelling of biotin with [18F]-FDG. Shoup et al (1994) have described the conjugation of biotin with mesylate to facilitate 18F-labelling using nucleophilic substitution. They suggested that 18F-biotin may be useful means of imaging infection. However 18F-fluorination using nucleophilic substitution requires stringent conditions including high temperature and the use of organic solvents.  More recently Ting et al (2005) functionalised biotin with a pinacol phenylboronate diester then fluorinated the compound in aqueous conditions but this group later showed that this compound was readily defluorinated (Ting et al 2008). To increase the stability of the B-18F bonds the use of 2,6-difluoro-4-carboxyphenylboronic acid, which include electron withdrawing atoms linked via ethylenediamine to biotin (Harwig et al 2008) were tested these proved less readily 18F-fluorinated but the B-18F bond formed was more stable. Thus Ting et al (2008) labeled tetraphenylpinacolyl arylboronate (0.3µmoles) using 18F over a 159min incubation period at 37oC and produced only a 15% labeling efficiency (based on product activity versus free [18F]-fluoride). We produced labeling efficiencies (also based on product activity versus free [18F]-fluoride) of 50 and 70% after 1h at room temperature using 0.1 and 0.5 µmoles respectively using a pinacol group linked to biotin via a PEG linker. PEGylation increases water solubility so this may also have contributed to improving the 18F-fluorination efficiency. 

Biotinidase-resistant biotin has been the subject of a series of recent papers using longer tracer to imaging times or therapy with long-lived radionuclides. This may not be an issue with short lived 18F where administration to scan times need to be short limiting exposure of biotin to biotinidases. However the use of biotinidase-resistant biotin is a potential modification that could be carried out prior to in-vivo application of 18F-PEG-biotin (Pratesi et al 2010).

Avidin has a high pI and is appreciably glycosylated. Both of these characteristics result in non-targeted interactions with cells (Marttila et al 2000). Although NeutravidinTM, does not possess carbohydrate moieties and has a neutral pI previous at least one study (Watlick et al 2004) suggests that non-specific binding can still be a problem so we included biotin-saturated NeutravidinTM during the incubation of cells with NeutravidinTM –conjugated trastuzumab to saturate the non-HER-2 NeutravidinTM-binding sites so reducing non-specific binding.    
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Scheme 1) Pathway for the synthesis of BA-PEG-biotin.

Figure 1) Labelling efficiency (percentage of product associated 18F) with time (h) using 0.1mg (triangles) and 0.5mg (squares) of BA-PEG-biotin (n=3). 

Figure 2) HPLC trace of  sample taken from a 30min reaction of BA-PEG-biotin with 18F-fluoride using UV detection at 210 nm (A) and using scintilation detection (B). X-(axis:Retention time (min)).

Figure 3) TLC trace from sample taken from a 30min reaction of BA-PEG-biotin with 18F-fluoride and developed using ethanol: water (95%:5%).  Distance migrated (in mm) versus radioactivity (in mV).
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